Sionna Therapeutics Presents CF Research at NACFC Conference

WALTHAM, Mass., Oct. 08, 2026 /CourierPR/ -- Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel medicines for cystic fibrosis (CF), will present new data at the 2026 North American Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia. The company will discuss its ongoing research and findings related to its NBD1 stabilizers and their potential to benefit people with CF.

The session is part of the S09 - Approaches to Increasing CFTR Expression & Function, and is scheduled for Thursday, October 8, 2026, from 4:30 p.m. to 6:30 p.m. Eastern Time.

Dr. Sawicki's presentation will summarize post hoc analyses of the PreciSION CF Phase 2a trial, which evaluated the addition of SION-719, a NBD1 stabilizer, to Trikafta. Although the trial did not achieve its key activity endpoint, post hoc analyses excluding three participants with potential dosing non-adherence showed a mean placebo-adjusted sweat chloride reduction of 8.6 mmol/L. The analyses also indicated lower exposures of all three Trikafta components during SION-719 treatment periods, suggesting a complex four-drug interaction. Additionally, there was a potential interaction between the NBD1 stabilizer SION-719 and the potentiator, ivacaftor, which may have reduced the additional benefit of NBD1 stabilization.

These findings, alongside preclinical data presented by Steve Altmann, support the advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial. This open-label, 28-day trial will assess sweat chloride, safety, and pharmacokinetics (PK) in adults with CF homozygous for F508del. The trial is expected to begin in the first quarter of 2027.

The poster, authored by S. Altmann, S. Bercury, J. Foley, Z. Gao, A. Hunnicutt, Liao, A. Madanjian, M. Munson, G. Topalov, and G. Hurlbut, will be presented at the NACFC. The study demonstrated that NBD1-stabilizer combinations improved CFTR trafficking and function up to wild-type levels, supporting their potential to benefit a broad population of people with CF.

The company's research and development efforts are part of its mission to revolutionize the treatment paradigm for CF by directly stabilizing the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna believes that NBD1 biological activity, as evidenced by the PreciSION CF trial and preclinical data, could lead to meaningful improvements in clinical outcomes and quality of life for people with CF.